Construction of an mRNA vaccine encoding hemagglutinin of influenza A H1N1 virus and investigation on booster immunization strategy

doi:10.3969/j.issn.1674-8115.2023.11.005

Abstract

Abstract:

Objective ·To construct an mRNA vaccine encoding hemagglutinin (HA) of influenza A H1N1 virus, and explore the protective effects of different booster vaccination strategies. Methods ·Firefly luciferase (Fluc) was used as the reporter gene to construct Fluc mRNA vaccine enveloped in lipid nanoparticles (LNP). The in vivo expression of Fluc mRNA-LNP after intramuscular injection was determined by live imaging assay in mice. Furthermore, M15-HA mRNA-LNP derived from H1N1 subtype (A/Michigan/45/2015) was constructed. Mice were immunized with 20, 10, 5, or 1 μg doses of M15-HA mRNA-LNP twice (with an interval of 3 weeks) through intramuscular injection. Serum antibody titers were measured by enzyme-linked immunosorbent assay (ELISA) at 2 weeks and 4 weeks after the second immunization, and functional antibody levels were detected by hemagglutination inhibition test. The third booster vaccination was performed 40 d after the second immunization in 1 μg dose group with 1 μg M15-HA mRNA-LNP or 10 μg HA subunit vaccine. The levels of specific antibody and functional antibody were detected by ELISA and hemagglutination inhibition test, respectively 2 weeks and 4 weeks later. Results ·Live imaging assay showed that luciferase activity could be detected in mice 1 d after injection of Fluc mRNA-LNP. At 2 weeks and 4 weeks after the second immunization of M15-HA mRNA-LNP, HA-specific antibodies were significantly higher than those before the immunization in all vaccination groups at different doses (P=0.000). The hemagglutination inhibition test showed that the levels of functional antibodies in the 20 μg dose and 10 μg dose groups were significantly higher than those in the PBS control group (P<0.05). After 1 μg dose group mice were immunized with HA protein or M15-HA mRNA-LNP, higher levels of HA-specific antibody and functional antibody were induced and maintained for a long time. There was no significant difference between the two different booster immunization strategies. Conclusion ·M15-HA mRNA-LNP vaccine is constructed with immunogenicity and antibody neutralization activity. Low-dose mRNA priming vaccination followed by both homologous mRNA vaccine and heterologous protein subunit vaccine booster vaccination can induce stronger immune recall responses.

Key words: influenza vaccine, influenza A virus, hemagglutinin, mRNA vaccine, booster immunization

CLC Number:

R392.12

SHEN Haiqian, YU Kangying, CHEN Yingying, JI Ping, WANG Ying. Construction of an mRNA vaccine encoding hemagglutinin of influenza A H1N1 virus and investigation on booster immunization strategy[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(11): 1374-1383.

Figures/Tables 7

Fig 1 Preparation and identification of FLuc mRNA-LNP

Fig 2 Detection of luciferase activity in mice at different days after intramuscular injection of FLuc mRNA-LNP

Fig 3 Preparation and identification of M15-HA mRNA-LNP

Fig 4 Determination of serum antigen-specific IgG antibody titers in M15-HA mRNA-LNP-vaccinated mice

Fig 5 Determination of functional antibody titers in M15-HA mRNA-LNP-vaccinated mice by hemagglutination inhibition test

Fig 6 Determination of serum antigen-specific IgG antibody titers in mice after homologous or heterologous immunization

Fig 7 Determination of functional antibody titers in the mice after homologous or heterologous immunization by hemagglutination inhibition test

TrendMD

References 27

1	PAGET J, TAYLOR R J, et al. Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project[J]. Vaccine, 2022, 40(9): 1361-1369.
2	PAULES C I, SULLIVAN S G, SUBBARAO K, et al. Chasing seasonal influenza: the need for a universal influenza vaccine[J]. N Engl J Med, 2018, 378(1): 7-9.
3	MATHIEU E, RITCHIE H, ORTIZ-OSPINA E, et al. A global database of COVID-19 vaccinations[J]. Nat Hum Behav, 2021, 5(7): 947-953.
4	POLACK F P, THOMAS S J, KITCHIN N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine[J]. N Engl J Med, 2020, 383(27): 2603-2615.
5	LAU J J, CHENG S M S, LEUNG K, et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population[J]. Nat Med, 2023, 29(2): 348-357.
6	NORDSTRÖM P, BALLIN M, NORDSTRÖM A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study[J]. Lancet Reg Health Eur, 2021, 11: 100249.
7	AI J W, ZHANG H C, ZHANG Q R, et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern[J]. Cell Res, 2022, 32(1): 103-106.
8	HEKELE A, BERTHOLET S, ARCHER J, et al. Rapidly produced SAM^® vaccine against H7N9 influenza is immunogenic in mice[J]. Emerg Microbes Infect, 2013, 2(8): e52.
9	VOGEL A B, LAMBERT L, KINNEAR E, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses[J]. Mol Ther, 2018, 26(2): 446-455.
10	AREVALO C P, BOLTON M J, LE SAGE V, et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes[J]. Science, 2022, 378(6622): 899-904.
11	LEUNG A K K, HAFEZ I M, BAOUKINA S, et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core[J]. J Phys Chem C Nanomater Interfaces, 2012, 116(34): 18440-18450.
12	SCHOENMAKER L, WITZIGMANN D, KULKARNI J A, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability[J]. Int J Pharm, 2021, 601: 120586.
13	BADEN L R, EL SAHLY H M, ESSINK B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine[J]. N Engl J Med, 2021, 384(5): 403-416.
14	LIU X Q, LI Y H, WANG Z F, et al. Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults[J]. Cell Res, 2022, 32(8): 777-780.
15	GUI Y Z, CAO Y, HE J J, et al. Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial[J]. Life Metab, 2023, 2(3): load019.
16	Moderna announces interim phase 3 safety and immunogenicity results for mRNA-1010, a seasonal influenza vaccine candidate[EB/OL]. (2023-02-16)[2023-10-10]. https://news.modernatx.com/news/news-details/2023/Moderna-Announces-Interim-Phase-3-Safety-and-Immunogenicity-Results-for-mRNA-1010-a-Seasonal-Influenza-Vaccine-Candidate/default.aspx.
17	BURGER L. Sanofi says it's back to the drawing board on mRNA flu vaccines[EB/OL]. (2023-06-29)[2023-10-10]. https://www.nasdaq.com/articles/sanofi-says-its-back-to-the-drawing-board-on-mrna-flu-vaccines.
18	CureVac advances seasonal flu study to phase 2 in collaboration with GSK following selection of promising mRNA vaccine candidate with broad coverage[EB/OL]. (2023-09-12)[2023-10-10]. https://www.curevac.com/en/curevac-advances-seasonal-flu-study-to-phase-2-in-collaboration-with-gsk-following-selection-of-promising-mrna-vaccine-candidate-with-broad-coverage/.
19	Clinical trial of mRNA universal influenza vaccine candidate begins[EB/OL]. (2023-09-12)[2023-10-10]. https://www.nih.gov/news-events/news-releases/clinical-trial-mrna-universal-influenza-vaccine-candidate-begins.
20	TAKANO T, SATO T, KOTAKI R, et al. Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain[J]. Nat Commun, 2023, 14(1): 1451.
21	CLEMENS S A C, WECKX L, CLEMENS R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study[J]. Lancet, 2022, 399(10324): 521-529.
22	ATMAR R L, LYKE K E, DEMING M E, et al. Homologous and heterologous covid-19 booster vaccinations[J]. N Engl J Med, 2022, 386(11): 1046-1057.
23	PARK H J, BANG Y J, KWON S P, et al. Analyzing immune responses to varied mRNA and protein vaccine sequences[J]. NPJ Vaccines, 2023, 8(1): 84.
24	AL KHAMES AGA Q A, ALKHAFFAF W H, HATEM T H, et al. Safety of COVID-19 vaccines[J]. J Med Virol, 2021, 93(12): 6588-6594.
25	HOSSEINI R, ASKARI N. A review of neurological side effects of COVID-19 vaccination[J]. Eur J Med Res, 2023, 28(1): 102.
26	FRAIMAN J, ERVITI J, JONES M, et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults[J]. Vaccine, 2022, 40(40): 5798-5805.
27	SHINKAI M, SONOYAMA T, KAMITANI A, et al. Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: an interim report of phase 2/3, randomized, observer-blinded, noninferiority study[J]. Vaccine, 2022, 40(32): 4328-4333.